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Abstract
Metastatic epidural spinal cord compression (MESCC) is an oncologic emergency and if left untreated,
permanent paralysis will ensue. The treatment of MESCC is governed by disease, patient, and treatment
factors. Patient’s preferences and goals of care are to be weighed into the treatment plan. Ideally, a patient
with MESCC is evaluated by an interdisciplinary team promptly to determine the urgency of the clinical
scenario. Treatment recommendations must take into consideration the risk-benefit profiles of surgical in-
tervention and radiotherapy for the particular individual’s circumstance, including neurologic status, per-
formance status, extent of epidural disease, stability of the spine, extra-spinal disease status, and life
expectancy. In patients with high spinal instability neoplastic score (SINS) or retropulsion of bone fragments
in the spinal canal, surgical intervention should be strongly considered. The rate of development of motor
deficits from spinal cord compression may be a prognostic factor for ultimate functional outcome, and should
be taken into account when a treatment recommendation is made. The American College of Radiology
Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every
three years by a multidisciplinary expert panel. The guideline development and review include an extensive
analysis of current medical literature from peer-reviewed journals and the application of a well-established
consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by
the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to
recommend imaging or treatment.
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Summary of Literature Review
Metastatic epidural spinal cord compression
The axial skeleton is a commonly involved site inpatients with bone metastases. Progressive spinal me-
tastasis may result in epidural spinal cord compression,
and lead to paresis and paralysis if left untreated.1–3 The
treatment of metastatic epidural spinal cord compression is
determined by disease factors such as histology, site of
disease, extent of epidural disease, and extent of metastases
elsewhere. Patient factors such as the neurologic status,
Karnofsky Performance Status (KPS), and treatment fac-
tors, such as availability of qualified spine surgeon and
advanced radiotherapy equipment, also have to be consid-
ered. Patient’s preferences and goals of care are to be
weighed into the treatment plan. Ideally, the patient
with epidural spinal cord compression is evaluated by an
interdisciplinary team including a combination of radia-
tion oncologists, medical oncologists, spine surgeons, pain
medicine specialists, interventional radiologists, physiat-
rists, and palliative care professionals in a timely fashion
to determine the urgency of the clinical scenario.1–3 Treat-
ment recommendations must take into consideration the
risk-benefit profiles of surgical intervention and radiother-
apy for the particular individual’s circumstance, includ-
ing neurologic status, performance status, extent of epidural
disease, stability of the spine, extra-spinal disease status,
and life expectancy.1–3 In patients with high spinal insta-
bility neoplastic score (SINS)4 or retropulsion of bone
fragments in the spinal canal, surgical intervention should
be strongly considered. The rate of development of mo-
tor deficits from spinal cord compression may be a prog-
nostic factor for ultimate functional outcome5 and should be
taken into account when a treatment recommendation
is made.
The importance of a high index of suspicion in high-risk
patients and a prompt diagnosis of metastatic spinal cord
compression cannot be overemphasized.1–3 The key goal of
the treatment for metastatic epidural spinal cord compression
is prompt decompression of the spinal cord in an attempt to
prevent further deterioration of neurologic function or to
reverse the neurologic deficits. This can be accomplished by
surgical decompression with or without postoperative ex-
ternal beam radiotherapy (EBRT) or EBRT alone.6 Systemic
approaches such as chemotherapy, hormonal therapy, oste-
oclast inhibitors (OI), and radiopharmaceuticals, especially if
given alone, are deemed not appropriate in this clinical sce-
nario, since the goal of prompt decompression of the spinal
cord is very unlikely to be achieved. Systemic therapy after
appropriate local therapy for metastatic spinal cord com-
pression may be appropriate for the treatment of systemic
disease, depending on the clinical scenario. For most solid
tumors, except radiosensitive and chemosensitive tumors
such as hematologic tumors, germ cell tumors, and small cell
carcinoma, there is level 1 evidence to suggest that surgical
decompression followed by EBRT can yield superior func-
tional outcomes compared to EBRT alone.1–3 For patients
who have poor performance status or are not otherwise
suitable for surgical decompression, EBRT is regarded as a
reasonable option. However, there is controversy as to the
optimal dose schedules and fractionation that should be
used.7–13 For hematologic tumors such as lymphoma and
plasma cell tumors/myeloma, EBRT alone is effective in the
decompression of the spinal cord since those are radiosen-
sitive tumors.14,15
Stereotactic body radiation therapy (SBRT) is an emerging
therapy for spinal metastasis and has been used for the
treatment of metastatic epidural spinal cord compression ei-
ther as primary treatment, reirradiation treatment, or post-
operative treatment,16–20 with reasonable preliminary results
based on some retrospective studies and a prospective study
(reported only in abstract form)19 with short-term follow-up.
There are no comparative studies or randomized trials com-
paring EBRT and SBRT in these settings. More research is
needed to better define the role of SBRT in metastatic spinal
cord compression, either as primary treatment or in the
postoperative setting.
Recurrent/progressive spinal metastasis
after prior radiation therapy
With the improvement of systemic therapy, overall sur-
vival is improved in patients with metastatic cancer. As a
result, it is more common to encounter scenarios where
patients develop recurrent/progressive spinal metastases,
sometimes causing spinal cord compression, after prior
EBRT to the same index lesions. This presents a therapeutic
challenge, since further EBRT will increase the risk of ra-
diation myelopathy (RM), posing patient safety concerns.
Data from a retrospective study showed that the risk of RM
was zero after a biologically effective dose (BED) of £ 120
Gy2 when the interval was not shorter than six months and
the BED of each course was < 98 Gy2.21 However, due to the
relatively small number of patients in these studies and
the retrospective nature and relatively short follow-up peri-
ods of these studies, these datasets should be interpreted
with caution.
As in metastatic epidural spinal cord compression, an
interdisciplinary evaluation is crucial to determine the best
treatment option for the patient. The ultimate treatment
strategy is determined by disease factors such as histology,
site of disease, extent of epidural disease, and extent of
metastases elsewhere, patient factors such as the neurologic
status and KPS, and treatment factors such as availability of
spinal neurosurgeon and advanced radiotherapy equipment.
If there is evidence of spinal instability or metastatic epi-
dural spinal cord compression, surgical intervention should
be strongly considered even when reirradiation is being
considered. The patterns of progression of neurologic defi-
cits from spinal cord compression may be predictive of ul-
timate functional outcome and should be taken into account
when a treatment recommendation is made.5 Patient’s
preferences and goals of care are to be weighed into the
treatment plan.
SBRT can provide a means to effectively treat previously
irradiated spinal metastases, while still being able to minimize
the risk of RM, by adequately sparing the spinal cord.22–24
Favorable outcomes and toxicity profiles have been reported
after SBRT for recurrent/progressive spinal metastasis as sole
or postoperative treatment.20,22–25 However, all the studies
are retrospective with a majority of them including patients
treated for scenarios other than recurrent disease.22–24,26,27
Furthermore, nearly all studies have relatively short follow-
up, and studies comparing conventional strategies and SBRT
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are very limited.26,27 One of the biggest controversies is
spinal cord tolerance for SBRT in the reirradiation setting and
guidelines for practice have been defined to guide practice
allowing the cumulative BED to reach 140 Gy2 (normalized 2
Gy equivalent 70 Gy2/2) with certain caveats, in particular,
the SBRT component not exceeding 50 Gy2 (normalized 2
Gy equivalent 25 Gy2/2); however, more research is needed to
better define the role of SBRT and to determine the spinal
cord tolerance in the reirradiation setting.28,29 Apart from
surgical intervention with or without SBRT, SBRT alone,
systemic approaches such as chemotherapy, hormonal ther-
apy, OI, and radiopharmaceuticals are other treatment op-
tions, depending on the clinical scenario.
Variant 1
A 60-year-old man with stage IV non–small-cell lung
cancer with KPS 80 and known asymptomatic spinal metas-
tasis at T7 receives first line systemic therapy, then develops
severe pain from the T7 metastasis (Brief Pain Inventory: 8
out of 10) associated with moderate epidural spinal cord
compression leading to a gradual onset of sensory above the
umbilicus and bilateral lower extremity weakness (motor
power 4 out of 5). MRI of the thoracic spine shows no cere-
brospinal fluid (CSF) around the mildly deformed cord at T7.
PET/CT shows stable primary tumor in the lung and lung
metastases. No bony retropulsion.
Tables: ACR Appropriateness Criteria Metastatic Epidural Spinal Cord Compression
and Recurrent Spinal Metastasis
Clinical condition: Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis
Variant 1: 60-year-old man with stage IV non–small-cell lung cancer with KPS 80 and known asymptomatic
spinal metastasis at T7 received first line systemic therapy, then developed severe pain from the
T7 metastasis (Brief Pain Inventory: 8 out of 10) associated with moderate epidural spinal cord
compression leading to a gradual onset of sensory level above the umbilicus and bilateral lower
extremity weakness (motor power 4 out of 5). MRI of the thoracic spine showed no CSF around the
mildly deformed cord at T7. PET/CT showed stable primary tumor in the lung and lung metastases.
No bony retropulsion.
Treatment Rating1 Comments
Hospice after RT 3
EBRT alone 5
Systemic therapy and EBRT 5
Systemic therapy and OI and EBRT 5
Direct hospice placement 2
Systemic therapy alone 2
Systemic radiopharmaceuticals alone 2
Surgical intervention alone 4
Surgical intervention followed by EBRT 8
Systemic therapy and OI 3
SBRT alone 5
Surgical intervention followed by SBRT 5
EBRT dose
8 Gy/1 fraction 5
20 Gy/5 fractions 7
30 Gy/10 fractions 8
35 Gy/14 fractions 7
40 Gy/20 fractions 4
SBRT dose
15–18 Gy/1 fraction 5
20–24 Gy/2 fractions 5
21–27 Gy/3 fractions 7
20–30 Gy/5 fractions 7
Treatment Planning
CT simulation 8
Fluoroscopic simulation 5
Clinical simulation 4
Posterior field only 5
Anterior/posterior fields 7
Posterior obliques 7
SBRT (postoperative) 5
IMRT 3
Proton therapy to the bone metastasis 2
1Rating scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate.
CSF, cerebrospinal fluid; EBRT, external beam radiotherapy; IMRT, intensity-modulated radiation therapy; OI, osteoclast inhibitors;
RM, radiation myelopathy; RT, radiation therapy; SBRT, stereotactic body radiation therapy.
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This is a case of spinal cord compression involving a spinal
segment that has not been previously irradiated. Once spinal
cord compression is confirmed, the patient should be started
on corticosteroid and adequate analgesics promptly.1–3 This
patient has a good KPS and stable primary tumor and me-
tastases in the lungs. The results of the multi-institutional
phase III trial comparing surgical decompression and post-
operative EBRT and EBRT alone for patients with metastatic
epidural spinal cord compression can be applied to him.6
Therefore, surgical intervention and postoperative EBRT can
be considered, as this combination has been demonstrated to
yield better functional outcomes compared to EBRT alone.
The type of surgery to be offered, namely, separation surgery
or more extensive decompression surgery such as verteb-
rectomy, is determined by judgment of clinical scenario in-
cluding SINS,4 and the experience and expertise of the
treating center.
Surgical decompression also allows for prompt decom-
pression of the spinal cord but should be followed with
postoperative EBRT because of the substantial risk of re-
currence. If a qualified spine surgeon is not available to
perform a surgical decompression and a prompt transfer to a
tertiary care center is not possible, radiotherapy in the form of
EBRT alone may be considered but is considered to be
suboptimal treatment.1–3 Given the good KPS and stable
extraspinal disease of the patient, hospice care alone may
increase the risks of paralysis and/or progression if the patient
lives long enough and the epidural spinal cord compression
does not have local treatment. However, the patient may
benefit from referral to palliative care/pain service for pain
control along the course of his or her treatment. In the setting
of primary EBRT, due to the presence of spinal cord com-
pression, it is important to ascertain that the gross tumor is
adequately treated.
Therefore, computed tomography (CT) simulation is
commonly used provided that EBRT can be started promptly.
If it is not possible to start EBRT promptly using CT planning
or if CT simulation is not available, fluoroscopic simulation is
regarded as a reasonable alternative. In the postoperative
setting, the spinal cord is already decompressed and time is
needed for healing of the surgical wound. As a result, prompt
initiation of EBRT is not necessary. A CT simulation should
be used to plan EBRT. Single-fraction EBRT delivering a
dose of 8 Gy is deemed to be inadequate to prevent future
recurrent spinal cord compression given the lower BED
compared to multifraction EBRT, which can range from 20
Gy/5 fractions to 35 Gy/14 fractions. EBRT field arrange-
ments, anterior/posterior (AP/PA), and PA alone are com-
monly used. Posterior oblique treatment approach can also be
considered, as it is an easy, relatively conformal dosimetric
approach that can reduce the volume of radiotherapy dose
administered to the healed surgical wound and esophagus
within the EBRT field. However, it can also result in higher
lung dose. The treating physician will need to judge the risk
and benefit of each technique on each individual patient.
SBRT has been used as primary treatment for metastatic
epidural spinal cord compression from solid tumors causing
mild neurologic deficits with favorable preliminary out-
comes.16,18,19 However, a very robust infrastructure is re-
quired for the prompt execution of the SBRT process to
facilitate prompt initiation of treatment of this emergent
condition, and this is only possible in very few treatment
centers. Furthermore, it is unclear whether the long-term
outcomes are comparable to those achieved with surgical
intervention and postoperative EBRT or EBRT alone given
the need to underdose the portion of the spinal metastasis
abutting the spinal cord to avoid RM. In the postoperative
setting, if adequate resection of the epidural disease is
achieved, thereby creating a gap between the spinal metas-
tasis and the spinal cord, SBRT may be considered, although
more data and longer follow-up are required in order to es-
tablish this as one of the standard postoperative treatment
options.17,20
There is even more-limited data on the use of intensity-
modulated radiation therapy (IMRT) or proton beam therapy
for primary or postoperative treatment of metastatic epidural
spinal cord compression, and these modalities are best tested
in a clinical trial setting. Systemic radiopharmaceuticals and
osteoclast inhibition are not expected to decompress the
spinal cord compression. Although one study shows that
systemic OI may improve control of metastatic epidural
spinal cord compression,30 there is no conclusive evidence it
is helpful in this setting, and should not be considered a
specific therapy for existing spinal cord compression. Given
the fact that the patient has progressive disease in T7 and has
only had first line chemotherapy, further systemic therapy
may be considered (see Variant 1 table).
Variant 2
A 65-year-old woman with known multiple myeloma but
with no prior therapy develops gradual onset of a sensory
level in the lower chest and moderate bilateral lower-
extremity weakness (motor power 3 out of 5) over one week
from an epidural spinal cord compression at T5. There is
associated moderate pain (Brief Pain Inventory: 6 of 10).
MRI shows circumferential compression of the spinal cord by
myeloma. There is no evidence of vertebral compression
fracture. KPS is 70. Skeletal survey reveals several other sites
of asymptomatic lytic metastases throughout the axial and
appendicular skeleton.
This patient without a history of prior therapy presents
with extensive epidural spinal cord compression at T5 from
myeloma. The main goals of treatment are to decompress the
spinal cord and to control the pain. Steroid therapy should be
started promptly to decrease cord edema/inflammation and it
also has therapeutic effect against myeloma.15 Since plasma
cell tumors are very radiosensitive even to a low to moderate
dose of radiation, the most commonly offered treatment is
emergent EBRT after initiation of steroid therapy.3,15 Adding
OI to the treatment of multiple myeloma reduces pathologic
vertebral fractures and pain, and it can be considered in
conjunction with EBRT.31 In light of the slight risk of os-
teonecrosis of the jaw associated with OI administration, a
pretreatment dental evaluation to assess dentition and po-
tential risk prior to starting OI might be necessary. OI with
pamidronate or zoledronic acid are FDA approved for use in
multiple myeloma, but not denosumab. Surgical intervention
is generally not required unless present or impending spinal
instability is contributing to the cord compression and SINS
can provide guidance.4
Kyphoplasty is not indicated for this patient, since it is
usually considered for pathologic vertebral compression
fractures and is usually not offered in the setting of spinal
576 LO ET AL.
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cord compression.32 Systemic treatment should be consid-
ered given the presence of systemic disease and her reason-
ably good performance status. While there are no definitive
data to suggest the most appropriate RT dose, fractionation
schedules ranging from a single 8 Gy fraction to 40 Gy/20
fractions are all commonly used. Given the fact that the pa-
tient is relatively young and has reasonable performance
status and a good chance of having neurologic improvement
after EBRT,5 more fractionated regimens, such as 30 Gy/10
fractions or 35 Gy/14 fractions, delivering a higher BED, are
favored.14 CT simulation to accurately include the involved
vertebrae and account for body habitus in EBRT dose cal-
culation is most desirable. Fluoroscopic simulation is re-
garded as a reasonable alternative. Common EBRT field
arrangements, AP/PA, PA alone, and posterior obliques are
commonly used. A posterior oblique treatment approach may
be favored over an AP/PA or PA beam arrangement, as it is an
easy, relatively conformal dosimetric approach that can re-
duce the dose administered to the skin, and this may be
beneficial if spinal surgery may come into play in the later
course of the disease. However, it can also result in higher
lung dose.
Clinical condition: Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis
Variant 2: 65-year-old woman with known multiple myeloma but with no prior therapy develops gradual
onset of a sensory level in the lower chest and moderate bilateral lower-extremity weakness
(motor power 3 out of 5) over one week from an epidural spinal cord compression at T5.
There is associated moderate pain (Brief Pain Inventory: 6 of 10). MRI shows circumferential
compression of the spinal cord by myeloma. There is no evidence of vertebral compression
fracture. KPS is 70. Skeletal survey reveals several other sites of asymptomatic lytic
metastases throughout the axial and appendicular skeleton.
Treatment Rating1 Comments
Steroid therapy and EBRT, followed by OI and chemotherapy 8
Steroid therapy and EBRT, followed by chemotherapy 8
Steroid therapy and EBRT, followed by OI 6
Steroid therapy and EBRT 6
Steroid therapy and OI and chemotherapy 3
Steroid therapy and chemotherapy 3
Steroid therapy and OI 3
EBRT alone 5
Steroid therapy alone 3
OI alone 2
Hospice after EBRT 3
Observation 1
Surgical decompression alone 3
Surgical decompression, followed by EBRT 3
SBRT alone 2
Surgical decompression, followed by SBRT 2
Systemic radiopharmaceuticals alone 2
Direct hospice placement 2
EBRT dose
8 Gy/1 fraction 4
20 Gy/5 fractions 6
20 Gy/10 fractions 5 This treatment may be appropriate
but there was disagreement
among panel members on the
appropriateness rating as defined
by the panel’s median rating.
30 Gy/10 fractions 8
35 Gy/14 fractions 7
40 Gy/20 fractions 4
Treatment planning
CT simulation 8
Fluoroscopic simulation 7
Clinical simulation 4
Posterior field only 6
Anterior/posterior fields 7
Posterior obliques 7
SBRT 2
IMRT 2
Proton therapy to the bone metastasis 2
1Rating scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate.
CSF, cerebrospinal fluid; EBRT, external beam radiotherapy; IMRT, intensity-modulated radiation therapy; OI, osteoclast inhibitors;
RM, radiation myelopathy; RT, radiation therapy; SBRT, stereotactic body radiation therapy.
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The treating physician will need to judge the risk and
benefit of each technique in each individual patient. The use
of more sophisticated highly conformal approaches like
SBRT, IMRT, and protons—all of which are very labor in-
tensive in the treatment planning process—in an aim to es-
calate the radiation dose to a very radiosensitive tumor in an
emergent setting, is considered insufficiently studied3 (see
Variant 2 table).
Variant 3
A 75-year-old woman with known progressive metastatic
colon cancer resistant to two lines of systemic therapy de-
velops increased pain in the middle back and sudden onset of
total paralysis of bilateral lower extremity one week prior to
admission to hospital from a nursing home. Her KPS is 50.
The pain is rated 7 out of 10 on the Brief Pain Inventory. The
lower extremity power is 0 out of 5 and the sensory level is
located above the umbilicus. MRI of the spine shows diffuse
spinal metastasis and circumferential compression of the
spinal cord at T8 from bulky metastasis with no surrounding
CSF. She has no prior history of EBRT to T8. The CT scan
shows diffuse lung and liver metastases.
This is a case of established spinal cord compression at a
spinal level that has not been previously irradiated. This
patient developed sudden onset of total paralysis of bilateral
lower extremity one week prior to presenting to the radiation
oncologist. Data in the literature show that patients with
sudden onset of total paralysis of extremities from meta-
static epidural spinal cord compression are much less likely
to regain function after treatment.5 Furthermore, there is a
delay of one week, rendering functional recovery extremely
unlikely. The patient also has very poor KPS and has un-
controlled systemic disease after two lines of systemic
chemotherapy. The life expectancy is short. All the above
factors render an aggressive approach such as surgical de-
compression futile.
The only goal of treatment in this case is pain control with
no potential for functional recovery. Medications to aid
symptom control may include steroids and analgesics.
Steroid therapy, preferably high dose, is typically used in
managing severe spinal cord compression.3 EBRT is very
Clinical condition: Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis
Variant 3: 75-year-old woman with known progressive metastatic colon cancer resistant to two lines of
systemic therapy develops increased pain in the middle back and sudden onset of total
paralysis of bilateral lower extremity one week prior to admission to hospital from a nursing
home. Her KPS is 50. The pain is rated 7 out of 10 on Brief Pain Inventory. The lower
extremity power is 0 out of 5 and the sensory level is located above the umbilicus. MRI of the
spine shows diffuse spinal metastasis and circumferential compression of the spinal cord at T8
from bulky metastasis with no surrounding CSF. She has no prior history of EBRT to T8.
CT scan shows diffuse lung and liver metastases.
Treatment Rating1 Comments
Hospice after EBRT 8
EBRT alone 7
Direct hospice placement 6
Chemotherapy and EBRT 3
Chemotherapy and OI and EBRT 3
Chemotherapy alone 2
Systemic radiopharmaceuticals alone 2
Surgical intervention alone 2
Chemotherapy and OI 2
SBRT alone 2
EBRT dose
8 Gy/1 fraction 7
20 Gy/5 fractions 7
30 Gy/10 fractions 5
35 Gy/14 fractions 4
40 Gy/20 fractions 3
Treatment planning
CT simulation 8
Fluoroscopic simulation 7
Clinical simulation 5
Posterior field only 7
Anterior/posterior fields 7
Posterior obliques 7
SBRT 2
IMRT 2
Proton therapy to the bone metastasis 1
1Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate.
CSF, cerebrospinal fluid; EBRT, external beam radiotherapy; IMRT, intensity-modulated radiation therapy; OI, osteoclast inhibitors;
RM, radiation myelopathy; RT, radiation therapy; SBRT, stereotactic body radiation therapy.
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effective for pain control. Direct hospice placement can be
considered if pain can be adequately controlled by medi-
cations. Hospice placement after EBRT is also reasonable to
avoid the logistic difficulties of coming to the radiation
center for EBRT, although some hospices accommodate
palliative EBRT.33
Systemic radiopharmaceuticals, chemotherapy, or OI are
unlikely to offer benefit in a patient with very limited
lifespan and spinal cord compression. Due to the spinal
cord compression and the bulk of disease, CT simulation
and EBRT are a reasonable approach. Given the poor
prognosis, a single dose of 8 Gy may be considered as 20
Gy/5 fractions and 30 Gy/10 fractions, and longer frac-
tionation regimens such as 35 Gy/14 fractions and 40 Gy/20
fractions may not offer extra benefit, since long-term
toxicities are not an active concern in this case. Fluoro-
scopic simulation is regarded as a reasonable alternative.
Clinical simulation, defined as setting up of a patient at the
treatment machine without kilovoltage films, is usually not
preferred. Common EBRT field arrangements, AP/PA, PA,
and posterior obliques alone, are commonly used. Highly
conformal approaches like SBRT, IMRT, and protons may
not offer extra benefit given the expected poor prognosis,
the need for prompt treatment, and the limited data on these
approaches in this setting. Surgical intervention is usually
not offered in this setting due to the expected poor prog-
nosis, the limited life expectancy, and diffuse extent of
disease3 (see Variant 3 table).
Variant 4
A 45-year-old man with known metastatic renal cell car-
cinoma develops increased pain in the lower back. He has
received sunitinib for his systemic disease. His KPS is 80. The
pain is rated 8 out of 10 on the Brief Pain Inventory. There
are no associated sensory or motor deficits in the lower ex-
tremities. He has a history of palliative EBRT to spinal levels
T12–L2 to a dose of 30 Gy in 10 fractions one year prior to
this presentation. MRI shows progression of spinal metas-
tasis at L1 vertebral body, and there is no epidural extension
or vertebral compression fracture. CT scan shows that the
lungs are the only other organs with metastatic renal cell
carcinoma and they have demonstrated good response to
sunitinib.
The patient’s systemic disease appears to be stable other-
wise, and his KPS is 80. The recurrent spinal metastasis at the
L1 vertebral body is the only symptomatic site of disease.
Given the controlled extraspinal systemic disease and the
good performance status, the survival of this patient can
potentially extend beyond six months.
As a result, active treatment of the symptomatic lesion,
which will entail reirradiation of the spine, is indicated to
control his symptoms and to avoid further progression that
may lead to spinal cord compression. Reirradiation with
EBRT using conventional techniques poses an increased
risk of RM should the patient’s survival time exceed six
months. Means to treat this symptomatic L1 lesion include
surgical intervention, reirradiation with advanced radiation
techniques, or systemic anticancer interventions with drug
therapy or radiopharmaceuticals. Steroids, OI, and analge-
sics may improve pain control and should be considered.
Surgery may be considered if there is spinal instability
based on SINS, if the adjacent, irradiated bone appears
stable, and the patient’s life expectancy is > 3–6 months,
and if there is appropriate surgical expertise to extirpate the
recurrent L1 vertebral body metastasis if surgery is indi-
cated. The decision to proceed with surgery in this situation
is very nuanced; patients with involvement of the vertebral
body and posterior elements, other evidence of spinal in-
stability, or refractory symptoms may benefit from surgical
intervention if their performance status allows. Patients
with higher SINS may benefit from vertebrectomy followed
by stabilization.4 Surgery can provide rapid relief of de-
bilitating pain and may be considered given the patient’s
good performance status. There is a fair amount of infor-
mation to provide guidance for reirradiation of spinal me-
tastases.22–24,26,27
Goals of treatment include prevention of further pro-
gression of spinal metastasis and providing pain relief
while minimizing the risk of RM. Highly conformal
techniques like proton therapy, SBRT, or IMRT should be
considered if appropriate expertise and equipment are
available and if sustained positioning is achievable for the
patient. Ideally, the patient can be enrolled in a clinical
trial, if one is available. Different fractionation regimens
have been used in SBRT for reirradiation of recurrent
spinal metastasis, and they are all achievable provided the
cord tolerance could be respected. There are some studies
analyzing spinal cord tolerance in the reirradiation setting
based on real patient data using linear-quadratic (LQ)29
and generalized LQ models.28 The data obtained from
those analyses are yet to be validated further. Since there
is no spinal canal involvement in this case, systemic
therapies, including radiopharmaceuticals, could be given
either as an adjuvant therapy or alone if surgery is not
indicated and if pain can be controlled with analgesics. He
will likely benefit from further systemic drug therapy after
his recurrent spinal metastasis is treated, given the pre-
vious good response of his extraspinal disease to systemic
drug therapy and his good performance status (see Variant
4 table).
Variant 5
A 56-year-old postmenopausal woman with known meta-
static breast carcinoma, estrogen and progesterone recep-
tors and HER2 positive, develops increased pain in the upper
back and gradual onset of bilateral lower extremity weakness
(motor power 4 + out of 5) over more than two weeks. Her
KPS is 80. The pain is rated 7 out of 10 on the Brief Pain
Inventory. She has a history of palliative EBRT to spinal
levels T2–T6 to a dose of 30 Gy in 10 fractions two years
prior to this presentation. MRI shows progression of spinal
metastasis at T4, and there is epidural extension from the
vertebral body and left pedicle, compressing on the spinal
cord with no CSF surrounding the cord. There is no associ-
ated vertebral compression fracture. She has received two
lines of systemic therapy with stable metastatic disease in the
lungs and in multiple sites in the bones apart from the T4
vertebra on PET/CT.
This patient presents with epidural spinal cord compres-
sion from breast cancer in a previously irradiated spinal
segment. The main goals of treatment are reversal of neuro-
logic deficit, prevention of further progression of neurologic
ACR APPROPRIATENESS CRITERIA 579
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Clinical condition: Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis
Variant 4: 45-year-old man with known metastatic renal cell carcinoma develops increased pain in the
lower back. He has received sunitinib for his systemic disease. His KPS is 80. The pain is
rated 8 out of 10 on Brief Pain Inventory. There are no associated sensory or motor deficits
in the lower extremities. He has a history of palliative EBRT to spinal levels T12–L2 to a
dose of 30 Gy in 10 fractions one year prior to this presentation. MRI shows progression
of spinal metastasis at L1 vertebral body and there is no epidural extension or vertebral
compression fracture. CT scan shows that the lungs are the only other organs with
metastatic renal cell carcinoma and they have demonstrated good response to sunitinib.
Treatment Rating1 Comments
Surgical intervention alone 5
EBRT alone 3
Surgical intervention and EBRT 3
Surgical intervention and EBRT and systemic
radiopharmaceuticals
3
Systemic therapy, surgical intervention and EBRT 3
Systemic therapy and EBRT 3
SBRT alone 7
Surgical intervention and SBRT 5 This treatment may be appropriate but there was
disagreement among panel members on the
appropriateness rating as defined by the panel’s
median rating.
Surgical intervention and SBRT and systemic
radiopharmaceuticals
3
Systemic therapy, surgical intervention and SBRT 5 This treatment may be appropriate but there was
disagreement among panel members on the
appropriateness rating as defined by the panel’s
median rating.
Systemic therapy and SBRT 7
Systemic therapy and surgical intervention 6
Surgical intervention and systemic radiopharmaceuticals 4
Hospice after treatment (surgery or SBRT) of the spine 3
Systemic radiopharmaceuticals alone 2
Direct hospice placement 2
Systemic therapy alone 2
OI alone 2
EBRT dose
8 Gy/1 fraction 3
20 Gy/5 fractions 3
20 Gy/8 fractions 5 This treatment may be appropriate but there was
disagreement among panel members on the
appropriateness rating as defined by the panel’s
median rating.
25 Gy/10 fractions 5 This treatment may be appropriate but there was
disagreement among panel members on the
appropriateness rating as defined by the panel’s
median rating.
30 Gy/10 fractions 3
35 Gy/14 fractions 3
40 Gy/20 fractions 2
SBRT dose
15–18 Gy/1 fraction 7
20–24 Gy/2 fractions 7
21–27 Gy/3 fractions 7
25–40 Gy/5 fractions 7
Treatment planning
CT simulation 9
Fluoroscopic simulation 4
Clinical simulation 2
Posterior field only 2
Anterior/posterior fields 3
Posterior obliques 4
SBRT 8
IMRT 7
Proton therapy to the bone metastasis 5 This treatment may be appropriate but there was
disagreement among panel members on the
appropriateness rating as defined by the panel’s
median rating.
1Rating scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate.
CSF, cerebrospinal fluid; EBRT, external beam radiotherapy; IMRT, intensity-modulated radiation therapy; OI, osteoclast inhibitors;
RM, radiation myelopathy; RT, radiation therapy; SBRT, stereotactic body radiation therapy.
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Clinical condition: Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis
Variant 5: 56-year-old postmenopausal woman with known metastatic breast carcinoma, estrogen and
progesterone receptors, and HER2 positive develops increased pain in the upper back and gradual
onset of bilateral lower extremity weakness (motor power 4 + out of 5) over more than two
weeks. Her KPS is 80. The pain is rated 7 out of 10 on Brief Pain Inventory. She has a history
of palliative EBRT to spinal levels T2–T6 to a dose of 30 Gy in 10 fractions two years prior
to this presentation. MRI shows progression of spinal metastasis at T4 and there is epidural
extension from the vertebral body and left pedicle, compressing on the spinal cord with no
CSF surrounding the cord. There is no associated vertebral compression fracture. She has
received two lines of systemic therapy with stable metastatic disease in the lungs and in multiple
sites in the bones apart from the T4 vertebra on PET/CT.
Treatment Rating1 Comments
Surgical intervention alone 5
EBRT alone 3
Surgical intervention and EBRT 5
Surgical intervention and EBRT and systemic radiopharmaceuticals 4
Systemic therapy, surgical intervention and EBRT 4
Systemic therapy and EBRT 3
SBRT alone 5
Surgical intervention and SBRT 7
Surgical intervention and SBRT and systemic radiopharmaceuticals 5
Systemic therapy, surgical intervention and SBRT 8
Systemic therapy and SBRT 5
Systemic therapy and surgical intervention 5
Surgical intervention and systemic radiopharmaceuticals 4
Hospice after treatment (surgery or SBRT) of the spine 3
Systemic radiopharmaceuticals alone 2
Direct hospice placement 2
Systemic therapy alone 2
OI alone 2
EBRT dose
8 Gy/1 fraction 3
20 Gy/5 fractions 3
20 Gy/8 fractions 5 This treatment may be appropriate
but there was disagreement
among panel members on the
appropriateness rating as defined
by the panel’s median rating.
25 Gy/10 fractions 5 This treatment may be appropriate
but there was disagreement among
panel members on the
appropriateness rating as defined
by the panel’s median rating.
30 Gy/10 fractions 3
35 Gy/14 fractions 3
40 Gy/20 fractions 3
SBRT dose
15–18 Gy/1 fraction 7
20–24 Gy/2 fractions 7
21–27 Gy/3 fractions 7
25–40 Gy/5 fractions 7
Treatment planning
CT simulation 9
Fluoroscopic simulation 4
Clinical simulation 2
Posterior field only 3
Anterior/posterior fields 4
Posterior obliques 4
SBRT 7
IMRT 7
Proton therapy to the bone metastasis 2
1Rating scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate.
CSF, cerebrospinal fluid; EBRT, external beam radiotherapy; IMRT, intensity-modulated radiation therapy; OI, osteoclast inhibitors;
RM, radiation myelopathy; RT, radiation therapy; SBRT, stereotactic body radiation therapy.
ACR APPROPRIATENESS CRITERIA 581
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/08
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
deficits, and pain control. Given her good performance status
and potential for further systemic therapy, her lifespan is
expected to be longer than 6 to 12 months. Although a cure is
not anticipated, preservation of her lower extremity neuro-
logic function and good pain control during her anticipated
prolonged survival period is crucial to the patient. The
gradual progression of her neurologic deficit over more than
two weeks and her fairly good current lower extremity
strength suggest that with decompression of the spinal cord
there is a good possibility of regaining her lower extremity
strength to nearly its full extent and maintaining a good
ambulatory function.5
Prompt initiation of steroid therapy is indicated. A prompt
decompression of the spinal cord is crucial in the determi-
nation of the eventual neurologic outcome. In light of her
previous EBRT to the same region, further EBRT delivering
an efficacious dose to the site of spinal cord compression
using conventional techniques will result in an increased risk
of RM, especially when the patient is expected to have a
potentially long survival. Surgical decompression should be
offered in this situation given its ability to rapidly decom-
press the spinal cord and the increased risk of RM resulting
from reirradiation with the conventional EBRT option. The
type of surgery to be offered, namely separation surgery or more
extensive decompression surgery such as vertebrectomy, is
determined by judgment of the clinical scenario including
SINS,4 and the experience and expertise of the treating cen-
ter. After surgical decompression, close observation or
postoperative SBRT,17,20 if the expertise and equipment are
available, may be considered.
There is some data in the literature on postoperative SBRT
in the reirradiation setting and promising results have been
observed.17,20 However, comparative studies and random-
ized trials are lacking. There is also concern over RM, al-
though the reported incidence is very low even in the
reirradiation setting. Different fractionation regimens have
been used in SBRT for reirradiation of recurrent spinal
metastasis, and they are all achievable provided the cord
tolerance could be respected. There are some studies ana-
lyzing spinal cord tolerance in the reirradiation setting
based on real patient data using LQ29 and generalized LQ
models.28 The data obtained from those analyses are yet to
be validated further. SBRT has been used as primary
treatment for reirradiation of metastatic epidural spinal
cord compression from solid tumors, causing mild neuro-
logic deficits.19 However, the data is very limited in terms
of efficacy and safety, particularly in the setting of re-
irradiation. Furthermore, a very robust infrastructure is
required for the prompt execution of the SBRT process to
facilitate prompt initiation of treatment of this emergent
condition, and this is only possible in very few treatment
centers. This modality is best considered in a clinical trial in
this setting. Systemic radiopharmaceuticals are unlikely to
be an effective decompressive treatment in this setting.
Although one study shows that systemic OI may improve
control of metastatic epidural spinal cord compression,30
there is no conclusive evidence it is helpful in this setting,
and it should not be considered a specific therapy for ex-
isting spinal cord compression. Given the fact that the pa-
tient has progressive disease in T4 and has only had two
lines of systemic therapy, further systemic therapy may be
considered (see Variant 5 table).
Summary of Recommendations
 Metastatic epidural spinal cord compression will lead
to paresis and paralysis if left untreated and is an on-
cologic emergency.
 The aim of treatment is to provide prompt decom-
pression of the spinal cord to avoid neurologic deteri-
oration or to recover some neurologic function.
 Treatment recommendations must take into consider-
ation the risk-benefit profiles of surgical intervention
and radiotherapy for the particular individual’s cir-
cumstance.
 The rate of development of motor deficits from spinal
cord compression may be a prognostic factor for ulti-
mate functional status and should be taken into account
when a treatment recommendation is made.
 There is level 1 evidence to suggest that surgical de-
compression followed by external beam radiotherapy
(EBRT) can yield superior functional outcomes com-
pared to EBRT alone.
 EBRT is regarded as a reasonable option for patients
with poor performance status or who are unsuitable
candidates for decompression surgery.
 Stereotactic body radiotherapy (SBRT) has been used
as primary treatment for metastatic epidural spinal cord
compression from solid tumors causing mild neurologic
deficits with favorable preliminary outcomes, but there
is a risk of further neurologic deterioration during the
planning of this very labor-intensive procedure.
 SBRT has also been used as adjuvant treatment after
surgical decompression with favorable preliminary
outcomes and may be appropriate in patients with ad-
equate resection of the epidural disease, although more
data is required in order to establish this as one of the
standard postoperative treatment options.
 Recurrent/progressive spinal metastases in spinal seg-
ments that have received prior EBRT present a thera-
peutic challenge, since further EBRT will increase the
risk of radiation myelopathy (RM).
 If there is evidence of spinal instability or metastatic
epidural spinal cord compression, surgical intervention
should be strongly considered even when reirradiation
is being considered.
 SBRT as a primary or postoperative treatment can
provide a means to effectively treat previously irradi-
ated spinal metastases, while still being able to mini-
mize the risk of RM, by adequately sparing the spinal
cord, with favorable outcomes and toxicity profiles
reported.
 Nearly all studies on SBRT for recurrent/ progressive
spinal metastases have relatively short follow-up, and
studies comparing conventional strategies and SBRT
are very limited.
 There are limited studies analyzing spinal cord toler-
ance for SBRT in the reirradiation setting using indi-
vidual patient data, but they are subject to further
rigorous clinical validation.
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